Navigation Links
Cardiac Science Sets Date for Fourth Quarter, Year-End Results Release and Conference Call
Date:3/3/2010

BOTHELL, Wash., March 3 /PRNewswire-FirstCall/ Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, announced today that it will release its fourth quarter 2009 financial results on Thursday, March 11, 2010 after market close. The Company has scheduled a conference call with analysts and investors for 4:30 p.m. Eastern Time. During the call, Cardiac Science management will discuss the financial results for the fourth quarter as well as the current business outlook.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

To access the conference call, please dial 888.549.7880 and reference conference ID 4252130. Callers outside the U.S. can dial 480.629.9868. The call will also be webcast live at www.cardiacscience.com. An audio replay of the call will be available for 7 days following the call at 800.406.7325 for U.S. callers or 303.590.3030 for those calling from outside the U.S. The password required to access the replay is 4252130#. An archived webcast will also be available at www.cardiacscience.com for 90 days.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB, and YouTube at http://budurl.com/CSonYT.


     For more information,
     Company Contact:                  Investor Contact:
     Mike Matysik                      Matt Clawson
     Cardiac Science Corporation       Allen & Caron
     Senior Vice President and CFO     949.474.4300
     425.402.2009                      matt@allencaron.com

     Media Contact:
     Christopher Gale
     EVC Group Inc.
     646.201.5431
     203.570.4681
     cgale@evcgroup.com


    LOGO: http://www.cardiacscience.com/images/main_logo.gif

CSCX-F

SOURCE Cardiac Science Corporation

Back to top

RELATED LINKS
http://www.cardiacscience.com

'/>"/>

SOURCE Cardiac Science Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. New cardiac CT technology drastically reduces patient radiation exposure
2. Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial
3. Herbal Remedies Can Cause Cardiac Problems
4. Sudden Cardiac Arrest Foundation Launches First Virtual Affiliate
5. Study Questions FDA Approvals of Cardiac Devices
6. With Cardiac Rehab, More Is Better: Study
7. Study finds gender gap persists in cardiac care
8. Cooling may benefit children after cardiac arrest
9. Inhibition of GRK2 is protective against acute cardiac stress injuries
10. Resuscitation and Survival Rates from Out-of-Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol
11. Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: